Cellular Senescence in Age-Related Diseases: Pathophysiology and Therapeutic Approaches

Dear Colleagues,

Cellular senescence, discovered in the 1960s, is a homeostatic response triggered by aging-associated insults, such as genomic instability and telomere attrition. It is characterized by a stable cell cycle arrest, which prevents the proliferation of damaged cells, and profound phenotypic changes, such as the production of a complex mixture of biologically active secreted factors, referred to as the senescence-associated secretory phenotype (SASP). As cellular senescence, a central hallmark of aging, plays an important role in age-related diseases including diabetes, cardiovascular disease, cancer, and neurodegenerative diseases, interventions targeting senescence are potential therapies for these diseases. The finding of an increased life span in murine models after the removal of senescent cells underscored the utility of targeting senescence for therapeutic benefits. Several therapeutic approaches have been developed. These include the development of drugs that selectively eliminate senescent cells,  known as senolytics, the development of drugs that modulate the SASP, known as senomorphics, and the development of drugs that revert senescence to allow senescent cells to enter the cell cycle, known as senoreverters. This Special Issue welcomes articles that clarify the molecular and physiological properties of senescent cells, shed light on the role of cellular senescence in the pathophysiology of age-related diseases, or describe the development of novel therapeutic approaches targeting cellular senescence.

Dr. David J. Rademacher
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cellular senescence
• senescence-associated secretory phenotype
• aging
• senolytics
• senomorphics
• senoreverters
• therapeutics